Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that fish scale collagen peptide significantly promoted wound healing in mice, with the <1 kDa fractions enhancing collagen synthesis and reducing inflammation, suggesting potential clinical benefits.

This study found that finasteride use was significantly associated with the reporting of obstructive sleep apnea and insomnia compared to all other drugs in the FAERS database.

The document concludes that individualized Facial Feminization Surgery plans and comprehensive care are crucial for successful outcomes.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

This article reviews the challenges of treating frontal fibrosing alopecia and the potential role of hair transplantation, noting the lack of effective medical treatments and uncertainty surrounding transplant outcomes.

This review discusses various treatments for androgenic alopecia, highlighting FDA-approved options and other commonly used therapies, but reports no new clinical results.

This study observed a high prevalence of PCOS among young female-pattern hair loss patients and suggested that AMH levels might be more indicative of FPHL than traditional androgens.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

In this study, ovarian SAHA was found to be independently associated with a more insulin-resistant profile and increased risk of glucose abnormalities in women with PCOS, beyond common risk factors.

This study details a method for assessing the risk of modifications to pharmaceutical frame formulations by assigning a risk priority number using Failure Modes Effects Analysis, which estimates the severity and probability of changes impacting the formulation.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This study found that finasteride increased fetal arousal activity in late gestation sheep by suppressing pregnane steroid synthesis, suggesting reduced GABAA receptor-mediated inhibition.

In this study, researchers found that progesterone promotes breast tumor growth in mice through its metabolite 5αP, which can be blocked by the 5α-reductase inhibitor finasteride.

This paper discusses advancements in forensic hair analysis, emphasizing a novel DART–HRMS method that improves the accuracy and efficiency of detecting drug use timelines.

This review discusses the pathogenesis and clinical features of androgenetic alopecia, highlighting potential links to fibrosing alopecia and suggesting the need for combined therapeutic approaches; it reports no new clinical results.

This review discusses SAHA syndrome in women, characterized by seborrhea, acne, hirsutism, and/or androgenetic alopecia, and notes its similarity to polycystic ovary syndrome without reporting new clinical results.

In this study, both finasteride and hydroxychloroquine were found to be equally effective, safe, and well-tolerated first-line treatments for frontal fibrosing alopecia in female patients, with no significant differences in efficacy between the two therapies over six months.

This article evaluates clinical and scientific literature on post-finasteride syndrome, concluding that finasteride and dutasteride may cause persistent sexual, neurological, and physical adverse side effects in a subset of men.

This study used high-resolution ultrasound to investigate the pathophysiology of persistent erectile dysfunction in young men who used the drug finasteride, observing differences in erectile tissue homogeneity compared to control subjects without finasteride exposure.

This report discusses the potential overlap between chronic cutaneous lupus and frontal fibrosing alopecia, noting ongoing debate over the significance of their association without presenting new clinical results.

This study identified several previously unrecognized adverse events linked to ISO, including serious conditions such as Dandy-Walker syndrome and suicidal ideation, suggesting that safety measures and drug labeling should be updated.

In this study, the researchers discovered that specific polyamine depletion enhances stemness in hair follicle stem cells through a mechanism independent of mRNA translation.

This study developed a precise and sensitive HPLC-MS/MS method for analyzing the pharmacokinetics of perospirone hydrochloride in human plasma, establishing it as suitable for clinical studies.

This consensus document provides foundational position statements for dermatologic ultrasound but reports no clinical results; it aims to guide future evidence-based recommendations and guidelines.

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

This study found that formalin-induced pain in rats nearly eliminates testosterone in the brain and spinal cord by likely increasing 5α-reductase activity, but normalizes serum levels after 24 hours.

This study observed that fibrosing alopecia in a pattern distribution shows varied histological features and may resemble lichen planopilaris with initial diffuse distribution, potentially leading to scarring alopecia.

This study identified that spermidine-mediated activation of eIF5A by hypusination plays a significant role in Arabidopsis thaliana growth, flowering time, stress adaptation, and development, including changing root and aerial architecture.

This study reported that Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology significantly improved hair thickness, density, shine, and elasticity, while reducing hair loss by an average of 66.8% and enhancing hair growth by up to 32.5% in subjects with androgenic alopecia over nine months.